-

Thermo Fisher Scientific Introduces the 5L DynaDrive Single-Use Bioreactor to Simplify and Accelerate Process Development and Help Bring Therapies to Market Faster

First-of-its-kind bench scale bioreactor enabling productivity, scalability and efficiency supporting reduced environmental impact

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the 5L DynaDrive Single-Use Bioreactor (S.U.B.), designed to meet the evolving needs of modern bioprocessing. The 5L DynaDrive expands the company's robust portfolio of bioreactors, offering seamless scalability from 1 to 5,000 liters and accelerating bench-scale process development, while facilitating the cost-effective transition from bench to commercialization with consistent reactor design and film across all scales.

"The introduction of the 5L DynaDrive marks a significant advancement in our commitment to helping customers maximize productivity and accelerate time to market," said Ray Mercier, president of Thermo Fisher’s single-use technologies business. "With 25 years of experience in single-use technology, we are dedicated to meeting our customers' evolving needs. Our trusted innovations provide seamless scalability and enhanced efficiency, enabling customers to streamline their bioprocessing workflows and successfully develop and commercialize life-saving therapies."

The 5L DynaDrive single-use bioreactor is engineered to meet the diverse needs of large biopharma, Contract Development and Manufacturing Organizations (CDMOs), and small biotech companies. Its user-friendly design and benchtop size enables use with the HyPerforma™ G3Lab Controller to provide exceptional scalability and scalable proof of concept, affordably. With a 27% increase in productivity compared to glass bioreactors, the 5L DynaDrive combines small size with high performance and offers effective scale-up with consistent design, software, and film across all sizes. The robust, reliable solution utilizes biobased films built on Thermo Fisher’s existing Aegis™ film offerings and BioTitan Retention Devices, enabling minimized product loss and more sustainability.

To learn more about Thermo Fisher’s DynaDrive portfolio, please visit www.thermofisher.com/dynadrive.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact:
Kathy Bricaud
Phone: 442-359-6848
Email: kathy.bricaud@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact:
Kathy Bricaud
Phone: 442-359-6848
Email: kathy.bricaud@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom